Diazepam(DZP) antibody/antigen (BSA/OVA/KLH conjugated hapten)
anti-Diazepam(DZP) antibody and Carrier-coupled antigen/immunogen (hapten-carrier conjugates)
Go to Drugs of Abuse diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-SMT-203-1 | 1. BSA-Diazepam(DZP) 2. Anti-Diazepam(DZP) mouse monoclonal antibody | $2709.00 |
GMP-SMT-203-2 | 1. OVA-Diazepam(DZP) 2. Anti-Diazepam(DZP) mouse monoclonal antibody | $2709.00 |
GMP-SMT-203-3 | 1. BSA-Diazepam(DZP) 2. Anti-Diazepam(DZP) human monoclonal antibody | $2709.00 |
GMP-SMT-203-4 | 1. OVA-Diazepam(DZP) 2. Anti-Diazepam(DZP) human monoclonal antibody | $2709.00 |
GMP-SMT-203-Ag-1 | BSA-Diazepam(DZP) | $756.00 |
GMP-SMT-203-Ag-2 | OVA-Diazepam(DZP) | $756.00 |
GMP-SMT-203-Ab-1 | Anti-Diazepam(DZP) mouse monoclonal antibody | $1953.00 |
GMP-SMT-203-Ab-2 | Anti-Diazepam(DZP) human monoclonal antibody | $1953.00 |
Size: 1mg | 10mg | 100mg
Product Description
BSA-Diazepam(DZP)
Cat No. | GMP-SMT-203-Ag-1 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; |
Products description | Competitive immunoassay-validated hapten-carrier conjugates BSA-Diazepam(DZP) with anti-Hapten antibody. The hapten hapten-carrier conjugates BSA-Diazepam(DZP) had been validated with our anti-Hapten antibody Anti-Diazepam(DZP) mouse monoclonal antibody via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
OVA-Diazepam(DZP)
Cat No. | GMP-SMT-203-Ag-2 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; |
Products description | Competitive immunoassay-validated hapten-carrier conjugates OVA-Diazepam(DZP) with anti-Hapten antibody. The hapten hapten-carrier conjugates OVA-Diazepam(DZP) had been validated with our anti-Hapten antibody Anti-Diazepam(DZP) mouse monoclonal antibody via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Anti-Diazepam(DZP) mouse monoclonal antibody
Cat No. | GMP-SMT-203-Ab-1 |
Host of Antibody | Mouse IgG |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; Lateral flow immunoassay (LFIA); |
ELISA IC50 (ppb) | 0.9-1 |
Products description | The anti-Hapten antibody against hapten Diazepam(DZP) had been validated with our hapten hapten-carrier conjugates BSA-Diazepam(DZP) via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Anti-Diazepam(DZP) human monoclonal antibody
Cat No. | GMP-SMT-203-Ab-2 |
Host of Antibody | Human IgG1 |
Bioactivity validation | Competitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody; Lateral flow immunoassay (LFIA); |
ELISA IC50 (ppb) | 0.9-1 |
Products description | The anti-Hapten antibody against hapten Diazepam(DZP) had been validated with our hapten hapten-carrier conjugates BSA-Diazepam(DZP) via competitive ELISA test. |
Application | ELISA tests and other immunoassays; Lateral flow immunoassay (LFIA); LTIA Immunonephelometry Time-resolved Fluorescence Immunoassay (TRFIA) |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Biomarker Information
1. Diazepam (DZP) in In Vitro Diagnosis (IVD):
1.1 Diagnostic Marker:
Diazepam, a member of the benzodiazepine class of small molecules, holds a prominent position in the world of pharmaceuticals due to its versatile clinical applications. Beyond its primary role as a therapeutic agent, Diazepam assumes significance in the realm of in vitro diagnosis (IVD), serving a dual purpose as both a diagnostic marker and a control substance.
- Diagnostic Marker: Diazepam plays a pivotal role as a diagnostic marker within clinical settings. As a small molecule drug, it possesses distinctive chemical properties that make it amenable to precise quantification in biological samples such as blood or urine. This capability renders Diazepam a valuable tool for discerning the presence of the drug or its metabolites within a patient's biological matrix.
In clinical scenarios where patients have a history of Diazepam usage or potential misuse, accurate detection and measurement of Diazepam levels become paramount. This information provide insights into drug exposure, metabolism, and adherence to prescribed regimens. Diagnostic tests utilizing Diazepam as a marker can reveal whether therapeutic levels are being maintained or if deviations exist, aiding clinicians in making informed decisions about patient care.
1.2 Control Substance:
- Control Substance: Diazepam's utility extends beyond diagnostic markers; it also plays a crucial role as a control substance in various IVD assays and analytical methodologies. In the context of these diagnostic procedures, control substances are indispensable for calibration and validation purposes.
Diazepam's use as a control substance hinges on its well-characterized chemical composition and known concentrations. Laboratories and diagnostic facilities rely on these properties to ensure the accuracy, precision, and reproducibility of diagnostic tests. By using Diazepam as a reference point, technicians can verify that their equipment and processes are functioning optimally, guaranteeing the reliability of test results.
2. The Significance of Measuring Diazepam (DZP):
2.1 Patient Monitoring:
The meticulous measurement of Diazepam levels in patients is essential for several compelling reasons:
- Patient Monitoring: Diazepam's pharmacological properties necessitate precise quantification in a patient's bloodstream or urine. This quantification serves as a fundamental tool for healthcare practitioners, enabling them to monitor drug concentrations and ensure that patients are receiving optimal therapy. This is especially crucial in cases where Diazepam is prescribed for anxiety management or other conditions, as maintaining drug levels within the therapeutic range is paramount for effective treatment.
- Detection of Misuse or Abuse: Beyond therapeutic usage, Diazepam measurements are instrumental in detecting instances of misuse or abuse. Anomalous levels of Diazepam can serve as an early warning sign of substance misuse disorders. Clinicians can use these measurements to initiate timely interventions, including counseling and addiction management, to address patients' underlying issues.
2.2 Forensic Analysis:
- Forensic Analysis: In the realm of forensic science, Diazepam measurements become pivotal in cases involving accidents, crimes, or other incidents where the presence or absence of the drug is germane to the investigation. Determining whether Diazepam was a contributing factor in accidents or incidents can be crucial for legal proceedings and accident reconstructions.
2.3 Research and Development:
- Research and Development: Researchers and pharmaceutical entities heavily rely on Diazepam measurements during preclinical and clinical studies. These investigations illuminate Diazepam's pharmacokinetic and pharmacodynamic profiles, providing valuable insights into its efficacy, safety, and interactions with other substances. Such knowledge informs the development of safer and more efficacious therapeutic agents, enhancing patient care and treatment outcomes.
2.4 Quality Assurance:
- Quality Assurance: For pharmaceutical manufacturers, adhering to stringent quality control protocols is imperative. The measurement of Diazepam content in medications ensures compliance with regulatory standards and guarantees the safety and potency of Diazepam-based pharmaceutical products. This meticulous quality control is essential to safeguard patients' well-being and maintain the integrity of the pharmaceutical industry.
In summary, the quantification of Diazepam is indispensable for patient care, diagnostic accuracy, forensic investigations, pharmaceutical research, and quality assurance. Its role as both a diagnostic marker and a control substance underscores its significance in the multifaceted landscape of in vitro diagnosis, pharmaceutical science, and healthcare delivery. Accurate Diazepam measurements enable healthcare professionals, researchers, and regulatory authorities to uphold standards of safety, efficacy, and precision across various domains, ultimately benefiting patients and advancing medical knowledge.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.